Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus JUNIOR STRENGTH IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus JUNIOR STRENGTH IBUPROFEN.
ANSAID vs JUNIOR STRENGTH IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis involved in pain, inflammation, and fever.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
Oral: 200-400 mg every 4-6 hours as needed; maximum single dose 400 mg, maximum daily dose 1200 mg for OTC use.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is 2-4 hours in children; prolonged in neonates or hepatic impairment.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Renal excretion of conjugated metabolites (approximately 70-90%) and unchanged drug (<10%). Biliary/fecal excretion accounts for <10%.
Category C
Category D/X
NSAID
NSAID